Nicolas Whenham

Cliniques Universitaires Saint-Luc — Belgium

Medicine · Health Sciences

11h-index562citations27works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(13), Brain Metastases and Treatment(7), Cancer Genomics and Diagnostics(4), Cancer Treatment and Pharmacology(4), Renal cell carcinoma treatment(3)

Publications27 total

P06.09.B TRIAL IN PROGRESS: PHASE 1 DOSE-FINDING STUDY TO EVALUATE SAFETY AND TOLERABILITY OF CVGBM IN PATIENTS WITH NEWLY DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA
Neuro-Oncology·2023Open Access
Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy
Cancer/Radiothérapie·2023· 23 cited
Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics
Acta Neurochirurgica·2023· 20 cited
SMART Syndrome: Case Report and Review of the Literature
Journal of the Belgian Society of Radiology·2023· 5 citedOpen Access
Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey
Journal of Neuro-Oncology·2022· 10 cited
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study
BMC Cancer·2021· 10 citedOpen Access
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma
European Journal of Cancer·2021· 18 citedOpen Access
Dietary betaine reduces plasma homocysteine concentrations and improves bone strength in laying hens
British Poultry Science·2021· 18 citedOpen Access
Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a prospective cohort study
Research Square (Research Square)·2020Open Access
Central diabetes insipidus induced by temozolomide: A report of two cases
Journal of Oncology Pharmacy Practice·2020· 7 citedOpen Access
Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Neuro-Oncology·2020· 8 citedOpen Access
INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
Neuro-Oncology·2019· 180 citedOpen Access
Long-term survival after glioblastoma resection: hope despite poor prognosis factors
Journal of Neurosurgical Sciences·2019· 23 cited
LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410
Neuro-Oncology·2017· 13 citedOpen Access
QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA
Neuro-Oncology·2017· 1 citedOpen Access
Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
The Oncologist·2016· 17 citedOpen Access
Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy.
Journal of Clinical Oncology·2015· 1 cited
Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers
Annals of Oncology·2012· 124 citedOpen Access
PP 72 Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell
European Journal of Cancer·2011· 1 cited
8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial
European Journal of Cancer·2011· 1 cited
page 1 of 2Next →

Frequent Co-authors

Emmanuel Seront(8), Paul M. Clément(7), Martin J. van den Bent(6), Filip De Vos(6), Sylvie Rottey(6), Brieuc Sautois(6), Lionel D’Hondt(6), Marica Eoli(5), Juan Manuel Sepúlveda-Sánchez(5), Annemiek Walenkamp(5), Olivier Chinot(5), Paul Sanghera(5), Michael Weller(5), Jim Looman(5), Sarah Nuyens(5), Maarten Spruyt(5), Thierry Gorlia(5), Vassilis Golfinopoulos(5), Jean‐Marie Vandenbulcke(5), Laurette Renard(5)